Dynavax Reports Preclinical Study Publication of TLR9 Agonist for Treatment of Lung Cancer
Shots:
- Study involves assessing of inhaled TLR9 agonist with anti-PD-1 in mouse preclinical model- leading a long term survival in two different mouse lung tumour models
- Administration of SD-101 in lungs of mice with metastatic tumours results in ~90% reduction in tumour burden in lung and liver both enhancing survival time and survival rate of 90-100 days
- An unpublished P-1b study involving TLR9 agonist- DV281 for lung tumours and lung metastases has shown corresponding results in above models of inhaled DV281 being evaluated for advanced NSLC patients
Ref: Dynavax | Image: Market Exclusive
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com